Pre-clinical: Increase peripheral blood flow, stimulate spinal kappa-opioid receptors, and inhibit oxidative stress or activation of the C fiber. Clinical: Decrease the incidence and delay the development of grade 2 and above oxaliplatin-induced neurotoxicity in CRC after 8 cycles of oxaliplatin-based chemotherapy. The gene discussed is OPRK1; the disease is colorectal carcinoma.